Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 14/20 | 0.42 |
| ▸ | MAOA | P21397 | 14/20 | 0.42 |
| ▸ | MAOB | P27338 | 14/20 | 0.42 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.39 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | APEX1 | P27695 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17523288 | 0.78 | KDM1A (0.42) | KDM1AMAOAMAOBTSHRGAA | |
| SCHEMBL17523290 | 0.78 | KDM1A (0.42) | KDM1AMAOAMAOBTSHRGAA | |
| SCHEMBL10748346 | 0.75 | KDM1A (0.46) | KDM1AMAOAMAOBTSHRKMT2A | |
| SCHEMBL9644214 | 0.74 | NFKB1 (0.40) | KDM1AMAOAMAOBGAASMN1; SMN2 | |
| SCHEMBL17732414 | 0.73 | GAA (0.52) | MEN1CYP1A2TSHRKMT2AGAA | |
| SCHEMBL17589052 | 0.73 | GAA (0.52) | MEN1CYP1A2TSHRKMT2AGAA | |
| SCHEMBL17583802 | 0.73 | GAA (0.52) | MEN1CYP1A2TSHRKMT2AGAA | |
| SCHEMBL16056849 | 0.71 | KDM1A (0.37) | KDM1AMAOAMAOBTSHRKMT2A | |
| SCHEMBL17525850 | 0.71 | KDM1A (0.37) | KDM1AMAOAMAOBTSHRKMT2A | |
| SCHEMBL16066005 | 0.71 | KDM1A (0.37) | KDM1AMAOAMAOBTSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9334297-B2 | Chiral imidazolium salts for asymmetric catalysis | NORTHWESTERN UNIVERSITY (US) | 2016-05-10 | — | — | US | disclosed |
| US-20160075728-A1 | Chiral Imidazolium Salts for Asymmetric Catalysis | NATIONAL SCIENCE FOUNDATION | 2016-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160075728-A1 | Chiral Imidazolium Salts for Asymmetric Catalysis | NDC1, NUDC, NIT2 | KDM1A 3071/4885MAOA 1103/4885MAOB 1034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.